An Overview on the Genetic Determinants of Infertility
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis
bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis. -
Chromosomal Abnormality in Men with Impaired Spermatogenesis
Original Article Chromosomal Abnormality in Men with Impaired Spermatogenesis Dana Mierla, M.D.1, 2*, Dumitru Jardan, M.D.1, Veronica Stoian, Ph.D.2 1. Life Memorial Hospital, Bucharest, Romania 2. Department of Genetics, Faculty of Biology, University of Bucharest, Bucharest, Romania Abstract Background: Chromosomal abnormalities and Y chromosome microdeletions are re- garded as two most frequent genetic causes associated with failure of spermatogenesis in the Caucasian population. Materials and Methods: To investigate the distribution of genetic defects in the Romanian population with azoospermia or severe oligozoospermia, karyotype anal- ysis by G-banding was carried out in 850 idiopathic infertile men and in 49 fertile men with one or more children. Screening for microdeletions in the azoospermia factor (AZF) region of Y chromosome was performed by multiplex polymerase chain reaction (PCR) on a group of 67 patients with no detectable chromosomal abnormality. The results of the two groups were compared by a two-tailed Fisher’s exact test. Results: In our study chromosomal abnormalities were observed in 12.70% and 8.16% of infertile and fertile individuals respectively. Conclusion: Our data suggests that infertile men with severe azoospermia have higher incidences of genetic defects than fertile men and also patients from any other group. Infertile men with normal sperm present a higher rate of polymorphic variants. It is important to know whether there is a genetic cause of male infertility before patients are subjected to intracytoplasmic sperm injection (ICSI) or testicular sperm extraction (TESE)/ICSI treatment. Keywords: Chromosomal Abnormality, Chromosome Microdeletion, Male Infertility, Azoospermia, Oligozoospermia Citation: Mierla D, Jardan D, Stoian V. -
Non-Syndromic Monogenic Male Infertility
Acta Biomed 2019; Vol. 90, Supplement 10: 62-67 DOI: 10.23750/abm.v90i10-S.8762 © Mattioli 1885 Review Non-syndromic monogenic male infertility Giulia Guerri1, Tiziana Maniscalchi2, Shila Barati2, Gian Maria Busetto3, Francesco Del Giudice3, Ettore De Berardinis3, Rossella Cannarella4, Aldo Eugenio Calogero4, Matteo Bertelli2 1 MAGI’s Lab, Rovereto (TN), Italy; 2 MAGI Euregio, Bolzano, Italy; 3 Department of Urology, University of Rome La Sapien- za, Policlinico Umberto I, Rome, Italy; 4 Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy Summary. Infertility is a widespread clinical problem affecting 8-12% of couples worldwide. Of these, about 30% are diagnosed with idiopathic infertility since no causative factor is found. Overall 40-50% of cases are due to male reproductive defects. Numerical or structural chromosome abnormalities have long been associ- ated with male infertility. Monogenic mutations have only recently been addressed in the pathogenesis of this condition. Mutations of specific genes involved in meiosis, mitosis or spermiohistogenesis result in spermato- genic failure, leading to the following anomalies: insufficient (oligozoospermia) or no (azoospermia) sperm production, limited progressive and/or total sperm motility (asthenozoospermia), altered sperm morphology (teratozoospermia), or combinations thereof. Androgen insensitivity, causing hormonal and sexual impair- ment in males with normal karyotype, also affects male fertility. The genetic causes of non-syndromic mono- genic of male infertility are summarized in this article and a gene panel is proposed. (www.actabiomedica.it) Key words: male infertility, oligozoospermia, azoospermia, asthenozoospermia, teratozoospermia, spermato- genic failure, androgen insensitivity syndrome Introduction development. Genetic causes of male infertility are outlined in Table 1. -
Transcription Factors SOHLH1 and SOHLH2 Coordinate Oocyte Differentiation Without Affecting Meiosis I
Transcription factors SOHLH1 and SOHLH2 coordinate oocyte differentiation without affecting meiosis I Yong-Hyun Shin, … , Vasil Mico, Aleksandar Rajkovic J Clin Invest. 2017;127(6):2106-2117. https://doi.org/10.1172/JCI90281. Research Article Development Reproductive biology Following migration of primordial germ cells to the genital ridge, oogonia undergo several rounds of mitotic division and enter meiosis at approximately E13.5. Most oocytes arrest in the dictyate (diplotene) stage of meiosis circa E18.5. The genes necessary to drive oocyte differentiation in parallel with meiosis are unknown. Here, we have investigated whether expression of spermatogenesis and oogenesis bHLH transcription factor 1 (Sohlh1) and Sohlh2 coordinates oocyte differentiation within the embryonic ovary. We found that SOHLH2 protein was expressed in the mouse germline as early as E12.5 and preceded SOHLH1 protein expression, which occurred circa E15.5. SOHLH1 protein appearance at E15.5 correlated with SOHLH2 translocation from the cytoplasm into the nucleus and was dependent on SOHLH1 expression. NOBOX oogenesis homeobox (NOBOX) and LIM homeobox protein 8 (LHX8), two important regulators of postnatal oogenesis, were coexpressed with SOHLH1. Single deficiency of Sohlh1 or Sohlh2 disrupted the expression of LHX8 and NOBOX in the embryonic gonad without affecting meiosis. Sohlh1-KO infertility was rescued by conditional expression of the Sohlh1 transgene after the onset of meiosis. However, Sohlh1 or Sohlh2 transgene expression could not rescue Sohlh2-KO infertility due to a lack of Sohlh1 or Sohlh2 expression in rescued mice. Our results indicate that Sohlh1 and Sohlh2 are essential regulators of oocyte differentiation but do not affect meiosis I. -
The Role of Y Chromosome Deletions in Male Infertility
European Journal of Endocrinology (2000) 142 418–430 ISSN 0804-4643 INVITED REVIEW The role of Y chromosome deletions in male infertility Kun Ma, Con Mallidis and Shalender Bhasin Division of Endocrinology, Metabolism and Molecular Medicine, Department of Internal Medicine, Charles R Drew University of Medicine and Science, 1731 East 120th Street, Los Angeles, California 90050, USA (Correspondence should be addressed to K Ma; Email: [email protected]) Abstract Male infertility affects approximately 2–7% of couples around the world. Over one in ten men who seek help at infertility clinics are diagnosed as severely oligospermic or azoospermic. Recent extensive molecular studies have revealed that deletions in the azoospermia factor region of the long arm of the Y chromosome are associated with severe spermatogenic impairment (absent or severely reduced germ cell development). Genetic research into male infertility, in the last 7 years, has resulted in the isolation of a great number of genes or gene families on the Y chromosome, some of which are believed to influence spermatogenesis. European Journal of Endocrinology 142 418–430 Introduction of Infertility, with the objective of creating a standard protocol for the investigation of infertile couples. Normal Defective spermatogenesis is the result of a multitude of semen was classified as containing a sperm concentra- causes, such as diseases, malnutrition, endocrinological 6 tion of at least 20 × 10 /ml, of which more than 40% disorders, genetic defects or environmental hazards (1). are progressively motile, more than 60% are alive, and Genetic defects, such as mutations and chromosomal over 50% show normal morphology. In addition, the abnormalities, have been estimated to account for at 6 semen should contain no more than 1 × 10 /ml of white least 30% of male infertility (2). -
Genetic Disorders in Premature Ovarian Failure
Human Reproduction Update, Vol.8, No.4 pp. 483±491, 2002 Genetic disorders in premature ovarian failure T.Laml1,3, O.Preyer1, W.Umek1, M.HengstschlaÈger2 and E.Hanzal1 University of Vienna Medical School, Department of Obstetrics and Gynaecology, 1Division of Gynaecology and 2Division of Prenatal Diagnosis and Therapy, Waehringer Guertel 18-20, A-1090 Vienna, Austria 3To whom correspondence should be addressed. E-mail: [email protected] This review presents the genetic disorders associated with premature ovarian failure (POF), obtained by Medline, the Cochrane Library and hand searches of pertinent references of English literature on POF and genetic determinants cited between the year 1966 and February 2002. X monosomy or X deletions and translocations are known to be responsible for POF. Turner's syndrome, as a phenotype associated with complete or partial monosomy X, is linked to ovarian failure. Among heterozygous carriers of the fragile X mutation, POF was noted as an unexpected phenotype in the early 1990s. Autosomal disorders such as mutations of the phosphomannomutase 2 (PMM2) gene, the galactose-1-phosphate uridyltransferase (GALT) gene, the FSH receptor (FSHR) gene, chromosome 3q containing the Blepharophimosis gene and the autoimmune regulator (AIRE) gene, responsible for polyendocrinopathy-candidiasis-ectodermal dystrophy, have been identi®ed in patients with POF. In conclusion, the relationship between genetic disorders and POF is clearly demonstrated in this review. Therefore, in the case of families affected by POF a thorough screening, including cytogenetic analysis, should be performed. Key words: autosomal disorders/FSH receptor/inhibin/premature ovarian failure/X chromosome abnormalities TABLE OF CONTENTS diagnosis requires histological examination of a full-thickness ovarian biopsy (Metha et al., 1992; Olivar, 1996). -
Turner Syndrome Diagnosed in Northeastern Malaysia Kannan T P, Azman B Z, Ahmad Tarmizi a B, Suhaida M A, Siti Mariam I, Ravindran A, Zilfalil B A
Original Article Singapore Med J 2008; 49(5) : 400 Turner syndrome diagnosed in northeastern Malaysia Kannan T P, Azman B Z, Ahmad Tarmizi A B, Suhaida M A, Siti Mariam I, Ravindran A, Zilfalil B A ABSTRACT counselling, gonadal dysgenesis, short stature, Introduction: Turner syndrome affects about one Turner syndrome in 2,000 live-born females, and the wide range Singapore Med J 2008; 49(5): 400-404 of somatic features indicates that a number of different X-located genes are responsible for the INTRODUCTION complete phenotype. This retrospective study Turner syndrome, gonadal dysgenesis or gonadal agenesis highlights the Turner syndrome cases confirmed represents a special variant of hypergonadotrophic through cytogenetic analysis at the Human hypogonadism, and is due to the lack of the second sex Genome Centre of Universiti Sains Malaysia, from chromosome or parts of it. This syndrome affects about one 2001 to 2006. in 2,000 live-born females.(1) The wide range of somatic features in Turner syndrome indicates that a number of Methods: Lymphocyte cultures were set up using different X-located genes are responsible for the complete peripheral blood samples, chromosomes were phenotype.(2) The syndrome includes those individuals prepared, G-banded, karyotyped and analysed in with a phenotypic spectrum from female to male, with accordance to guidelines from the International varying clinical stigmata of the syndrome, as described System for Human Cytogenetic Nomenclature. by Turner.(3) Though many karyotype abnormalities have been described in association with Turner syndrome, Results: The various karyotype patterns observed monoclonal monosomy X and its various mosaicisms, Human Genome were 45,X; 46,X,i,(Xq); 45,X/45,X,+mar; each with an X monosomic (XO) cell clone, are the most Centre, Universiti Sains 45,X/46,X,i,(Xq) and 45,X/46,XY. -
Sex Chromosome Aneuploidies
7 Sex Chromosome Aneuploidies Eliona Demaliaj1, Albana Cerekja2 and Juan Piazze3 1Department of Obstetric-Gynecology, Faculty of Medicine, University of Tirana Hospital "Mbreteresha Geraldine", Tirane 2Gynecology and Obstetrics Ultrasound Division, ASL Roma B, Rome 3Ultrasound Division, Ospedale di Ceprano/Ospedale SS. Trinità di Sora, Frosinone 1Albania 2,3Italy 1. Introduction Sex chromosome aneuploidy is defined as a numeric abnormality of an X or Y chromosome, with addition or loss of an entire X or Y chromosome. Sex chromosome mosaicism, in which one or more populations of cells have lost or gained a sex chromosome, also is common. The most commonly occurring sex chromosome mosaic karyotypes include 45,X/46XX, 46XX/47,XXX, and 46,XY/47,XXY. Less frequent are those sex chromosome abnormalities where addition of more than one sex chromosome or a structural variant of an X or Y chromosome occur. The X chromosome is one of the two sex-determining chromosomes in many animal species, including mammals and is common in both males and females. It is a part of the XY and X0 sex-determination system. The X chromosome in humans represents about 2000 out of 20,000 - 25,0000 genes. Normal human females have 2 X-chromosomes (XX), for a total of nearly 4000 "sex-tied" genes (many of which have nothing to do with sex, other than being attached to the chromosome that is believed to cause sexual bimorphism (or polymorphism if you count more rare variations). Men have, depending on the study, 1400-1900 fewer genes, as the Y chromosome is thought to have only the remaining genes down from an estimated 1438 -~2000 (Graves 2004). -
Supplementary Materials
Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine -
Orphanet Report Series Rare Diseases Collection
Marche des Maladies Rares – Alliance Maladies Rares Orphanet Report Series Rare Diseases collection DecemberOctober 2013 2009 List of rare diseases and synonyms Listed in alphabetical order www.orpha.net 20102206 Rare diseases listed in alphabetical order ORPHA ORPHA ORPHA Disease name Disease name Disease name Number Number Number 289157 1-alpha-hydroxylase deficiency 309127 3-hydroxyacyl-CoA dehydrogenase 228384 5q14.3 microdeletion syndrome deficiency 293948 1p21.3 microdeletion syndrome 314655 5q31.3 microdeletion syndrome 939 3-hydroxyisobutyric aciduria 1606 1p36 deletion syndrome 228415 5q35 microduplication syndrome 2616 3M syndrome 250989 1q21.1 microdeletion syndrome 96125 6p subtelomeric deletion syndrome 2616 3-M syndrome 250994 1q21.1 microduplication syndrome 251046 6p22 microdeletion syndrome 293843 3MC syndrome 250999 1q41q42 microdeletion syndrome 96125 6p25 microdeletion syndrome 6 3-methylcrotonylglycinuria 250999 1q41-q42 microdeletion syndrome 99135 6-phosphogluconate dehydrogenase 67046 3-methylglutaconic aciduria type 1 deficiency 238769 1q44 microdeletion syndrome 111 3-methylglutaconic aciduria type 2 13 6-pyruvoyl-tetrahydropterin synthase 976 2,8 dihydroxyadenine urolithiasis deficiency 67047 3-methylglutaconic aciduria type 3 869 2A syndrome 75857 6q terminal deletion 67048 3-methylglutaconic aciduria type 4 79154 2-aminoadipic 2-oxoadipic aciduria 171829 6q16 deletion syndrome 66634 3-methylglutaconic aciduria type 5 19 2-hydroxyglutaric acidemia 251056 6q25 microdeletion syndrome 352328 3-methylglutaconic -
HARS2 Gene Histidyl-Trna Synthetase 2, Mitochondrial
HARS2 gene histidyl-tRNA synthetase 2, mitochondrial Normal Function The HARS2 gene provides instructions for making an enzyme called mitochondrial histidyl-tRNA synthetase. This enzyme is important in the production (synthesis) of proteins in cellular structures called mitochondria, the energy-producing centers in cells. While most protein synthesis occurs in the fluid surrounding the nucleus (cytoplasm), some proteins are synthesized in the mitochondria. During protein synthesis, in either the mitochondria or the cytoplasm, a type of RNA called transfer RNA (tRNA) helps assemble protein building blocks (amino acids) into a chain that forms the protein. Each tRNA carries a specific amino acid to the growing chain. Enzymes called aminoacyl-tRNA synthetases, including mitochondrial histidyl- tRNA synthetase, attach a particular amino acid to a specific tRNA. Mitochondrial histidyl-tRNA synthetase attaches the amino acid histidine to the correct tRNA, which helps ensure that histidine is added at the proper place in the mitochondrial protein. Health Conditions Related to Genetic Changes Perrault syndrome At least two mutations in the HARS2 gene have been found to cause Perrault syndrome. This rare condition is characterized by hearing loss in males and females with the disorder and abnormalities of the ovaries in affected females. The HARS2 gene mutations involved in Perrault syndrome reduce the activity of mitochondrial histidyl- tRNA synthetase. A shortage of functional mitochondrial histidyl-tRNA synthetase prevents the normal assembly of new proteins within mitochondria. Researchers speculate that impaired protein assembly disrupts mitochondrial energy production. However, it is unclear exactly how HARS2 gene mutations lead to hearing problems and ovarian abnormalities in affected individuals. -
Aminoacyl-Trna Synthetase Deficiencies in Search of Common Themes
© American College of Medical Genetics and Genomics ARTICLE Aminoacyl-tRNA synthetase deficiencies in search of common themes Sabine A. Fuchs, MD, PhD1, Imre F. Schene, MD1, Gautam Kok, BSc1, Jurriaan M. Jansen, MSc1, Peter G. J. Nikkels, MD, PhD2, Koen L. I. van Gassen, PhD3, Suzanne W. J. Terheggen-Lagro, MD, PhD4, Saskia N. van der Crabben, MD, PhD5, Sanne E. Hoeks, MD6, Laetitia E. M. Niers, MD, PhD7, Nicole I. Wolf, MD, PhD8, Maaike C. de Vries, MD9, David A. Koolen, MD, PhD10, Roderick H. J. Houwen, MD, PhD11, Margot F. Mulder, MD, PhD12 and Peter M. van Hasselt, MD, PhD1 Purpose: Pathogenic variations in genes encoding aminoacyl- with unreported compound heterozygous pathogenic variations in tRNA synthetases (ARSs) are increasingly associated with human IARS, LARS, KARS, and QARS extended the common phenotype disease. Clinical features of autosomal recessive ARS deficiencies with lung disease, hypoalbuminemia, anemia, and renal tubulo- appear very diverse and without apparent logic. We searched for pathy. common clinical patterns to improve disease recognition, insight Conclusion: We propose a common clinical phenotype for recessive into pathophysiology, and clinical care. ARS deficiencies, resulting from insufficient aminoacylation activity Methods: Symptoms were analyzed in all patients with recessive to meet translational demand in specific organs or periods of life. ARS deficiencies reported in literature, supplemented with Assuming residual ARS activity, adequate protein/amino acid supply unreported patients evaluated in our hospital. seems essential instead of the traditional replacement of protein by Results: In literature, we identified 107 patients with AARS, glucose in patients with metabolic diseases. DARS, GARS, HARS, IARS, KARS, LARS, MARS, RARS, SARS, VARS, YARS, and QARS deficiencies.